What the FDA’s Phase-Out of Animal Models in mAbs Studies Means for Drug Discovery Labs
In a move that could reshape the landscape of preclinical drug development, the Food and Drug Administration (FDA) recently announced a plan to phase out its requirement for use of animal models in evaluating monoclonal antibodies (mAbs) and other drug candidates.